LifeVantage Corp. 10-Q Summary: Quarter Ended March 31, 2025
Business Context and Reporting Period
This filing is a Quarterly Report on Form 10-Q for LifeVantage Corporation (LFVN) for the period ended March 31, 2025. LifeVantage is a nutrigenomics company operating a direct sales model globally, selling dietary supplements, skin care, and wellness products through a network of independent consultants. The company is classified as a smaller reporting company.
Key Financial Metrics
| Metric | Three Months Ended Mar 31, 2025 | Nine Months Ended Mar 31, 2025 |
|---|---|---|
| Net Revenue | $58.4 million | $173.4 million |
| Gross Profit | $47.3 million (81.0% margin) | $139.6 million (80.5% margin) |
| Operating Income | $4.1 million | $10.1 million |
| Net Income | $3.5 million | $7.8 million |
| Diluted EPS | $0.26 | $0.60 |
| Cash and Equivalents | $22.5 million (as of Mar 31, 2025) | N/A |
| Operating Cash Flow | N/A | $10.8 million |
| Debt Outstanding | $0 (Credit facility unused) | $0 |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 21.1% year-over-year for the quarter and 14.7% for the nine-month period. Growth was primarily driven by the launch of the MindBody GLP-1 System in the U.S. (October 2024) and Japan (March 2025).
- Regional Performance:
- Americas: Revenue grew 29.5% (quarter) and 23.9% (nine months), fueled by the MindBody GLP-1 launch and a 17.2% increase in active accounts.
- Asia/Pacific & Europe: Revenue declined 7.2% (quarter) and 14.5% (nine months) due to a decrease in active accounts and negative foreign currency impacts, partially offset by new product launches.
- Expense Trends:
- Commissions: Increased to 44.8% of revenue (quarter) from 40.9% prior year, attributed to higher qualifications in incentive programs and sales mix changes.
- SG&A: Decreased as a percentage of revenue to 29.2% (quarter) from 34.0% prior year, driven by reduced proxy contest expenses and the termination of a sports endorsement agreement.
- Liquidity: Cash and cash equivalents increased by $5.6 million to $22.5 million compared to the prior fiscal year-end. Working capital improved to $21.5 million.
Outlook, Risks, and Management Commentary
- Product Strategy: Management is focusing on "stack" strategies (bundling products) and expanding the MindBody GLP-1 System internationally in the fourth quarter of fiscal 2025.
- Capital Allocation: The company continues to return capital to shareholders via dividends ($0.04 per share quarterly) and share repurchases. As of March 31, 2025, $19.3 million remained available under the $60.0 million repurchase program.
- Debt Facility: The company maintains a $5.0 million revolving credit facility with Bank of America, which remains undrawn. The company is in compliance with all financial covenants.
- Risks: Key risks include dependence on independent consultants, foreign currency fluctuations, supply chain disruptions, and the ability to retain active accounts in international markets. The filing notes no material changes to risk factors from the previous 10-K.
Investor Verification Checklist
- Active Account Trends: Verify the sustainability of the 10.2% increase in total active accounts, noting the divergence between growth in the Americas and decline in Asia/Pacific & Europe.
- Commission Ratios: Monitor the rising commission expense ratio (44.8% vs 40.9% prior year) to ensure it does not erode operating margins as incentive programs evolve.
- Product Mix Impact: Assess the long-term revenue contribution of the MindBody GLP-1 System versus legacy products like Protandim.
- Currency Exposure: Review the impact of foreign exchange rates on the Asia/Pacific & Europe region, which negatively impacted revenue by approximately $0.5 million in the quarter.
- Share Repurchase Activity: Track the utilization of the remaining $19.3 million repurchase authorization, noting no shares were repurchased in the most recent quarter.